New Drug Indications - February 2022


abatacept

Orencia

Pharmaceutical company: Bristol-Myers Squibb

NEW INDICATION & DOSAGE

Prophylaxis of acute graft-versus-host disease, in combination with a calcineurin inhibitor and methotrexate, in patients undergoing hematopoietic stem cell transplantation from a matched or 1 allele-mismatched unrelated donor

Adults and children age 6 and older: 10 mg/kg dose (maximum dose 1,000 mg) IV infusion over 60 minutes on the day before transplantation, followed by a dose on days 5, 14, and 28 after transplant.

Children ages 2 to less than 6: 15 mg/kg dose IV infusion over 60 minutes on the day before transplantation, followed by 12 mg/kg on days 5, 14, and 28 after transplant.

Released: February 2022

Nursing Drug Handbook

© 2022 Wolters Kluwer


budesonide

Tarpeyo

Pharmaceutical company: Calliditas Therapeutics

NEW AVAILABLE FORM

Delayed-release capsules: 4 mg

INDICATION & DOSAGE

Proteinuria in patients with primary immunoglobulin A nephropathy at risk for rapid disease progression

Adults: 16 mg PO daily in the morning at least 1 hour before a meal.

Adjust-a-dose: Reduce dose to 8 mg daily for 2 weeks before discontinuing the drug.

Released: February 2022

Nursing Drug Handbook

© 2022 Wolters Kluwer


carfilzomib

Kyprolis

Pharmaceutical company: Amgen, Inc.

NEW INDICATION & DOSAGE

Relapsed or refractory multiple myeloma in combination with daratumumab and hyaluronidase-fihj and dexamethasone after one to three prior lines of therapy

Adults: For twice-weekly 20/56 mg/m2 regimen, give as a 30-minute IV infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle in combination with subcut daratumumab and hyaluronidase-fihj, and dexamethasone until disease progression or unacceptable toxicity occurs. Initially, give 20 mg/m2 on cycle 1, days 1 and 2. If tolerated, escalate to 56 mg/m2 on cycle 1, day 8 and thereafter. Give dexamethasone 30 minutes to 4 hours before carfilzomib and 1 to 3 hours before IV daratumumab and hyaluronidase-fihj.

For once-weekly 20/70 mg/m2 regimen, give as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day cycle in combination with subcut daratumumab and hyaluronidase-fihj, and dexamethasone until disease progression or unacceptable toxicity occurs. Initially, give 20 mg/m2 on cycle 1, day 1. If tolerated, escalate to 70 mg/m2 on cycle 1, day 8 and thereafter. Give dexamethasone 30 minutes to 4 hours before carfilzomib and 1 to 3 hours before IV daratumumab and hyaluronidase-fihj.

Adjust-a-dose: Refer to the manufacturer's instructions for daratumumab and hyaluronidase-fihj for dosage information.

Released: February 2022

Nursing Drug Handbook

© 2022 Wolters Kluwer


clindamycin phosphate

Xaciato

Pharmaceutical company: Daré Biosciences

NEW FORMULATION

Gel: 2%

INDICATION & DOSAGE

Bacterial vaginosis

Adults and children age 12 and older: 1 applicatorful vaginally as a single dose.

Released: February 2022

Nursing Drug Handbook

© 2022 Wolters Kluwer


elbasvir–grazoprevir

Zepatier

Pharmaceutical company: Merck Sharp & Dohme Corp

NEW INDICATION & DOSAGE

Chronic hepatitis C virus (HCV) genotypes 1 or 4 infection, with or without ribavirin

Children age 12 and older or weighing at least 30 kg: 1 tablet PO once daily. See manufacturer's instructions for recommended dosing regimens and durations for treatment of HCV genotype 1 or 4 in patients with or without cirrhosis.

Adjust-a-dose: If ALT level is greater than 10 times the upper limit of normal, consider discontinuing the drug. If ALT level is elevated and accompanied by signs or symptoms of liver inflammation, increased conjugated bilirubin or alkaline phophatase level, or increased INR, discontinue the drug. If creatinine clearance is 50 mL/minute or less and ribavirin is used, refer to ribavirin prescribing information for ribavirin dose adjustment.

Released: February 2022

Nursing Drug Handbook

© 2022 Wolters Kluwer

pembrolizumab

Keytruda

Pharmaceutical company: Merck & Co.

NEW INDICATION & DOSAGE

Adjuvant treatment of melanoma with lymph node involvement after complete resection

Children age 12 and older: 2 mg/kg IV over 30 minutes every 3 weeks up to maximum dose of 200 mg. Continue until disease recurrence or unacceptable toxicity occurs, or up to 12 months in patients without disease recurrence.

Released: February 2022

Nursing Drug Handbook

© 2022 Wolters Kluwer


rituximab

Rituxan

Pharmaceutical company: Genentech

NEW INDICATION & DOSAGE

Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia in combination with chemotherapy

Children age 6 months and older: 375 mg/m2 IV infusion in combination with systemic Lymphome Malin B chemotherapy. Give the drug on day 2 and day 1 (48 hours apart) of each of the induction courses, and on day 1 of each of the two consolidation courses. Give prednisone component of regimen before rituximab. Refer to the manufacturer's instructions for additional dosing information.

Released: February 2022

Nursing Drug Handbook

© 2022 Wolters Kluwer


tofacitinib

Xeljanz and Xeljanz XR

Pharmaceutical company: Pfizer

NEW INDICATION & DOSAGE

Ankylosing spondylitis after inadequate response or intolerance to one or more tumor necrosis factor blockers

Adults: 5 mg (immediate-release) PO twice daily. Or, 11 mg (extended-release) PO once daily.

Adjust-a-dose: Reduce dosage to 5 mg (immediate-release) PO daily in patients with moderate to severe renal impairment or moderate hepatic impairment in those receiving concurrent potent CYP3A4 inhibitors, and in those receiving a moderate CYP3A4 inhibitor with a strong CYP2C19 inhibitor.

Released: February 2022

Nursing Drug Handbook

© 2022 Wolters Kluwer